Screener
MapLight Therapeutics, Inc. MPLT EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by MapLight Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: MapLight Therapeutics, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:25 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224129
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest income | 2,472 | 811 |
| Other income, net | 1,363 | 392 |
| Net loss | $(60,668) | $(22,340) |
| Net loss per share - basic and diluted | $(1.34) | $(29.33) |
| Weighted-average number of common shares outstanding - basic and diluted | 45,276,763 | 761,598 |
| Comprehensive loss: | ||
| Net loss | $(60,668) | $(22,340) |
| Other comprehensive loss: |
Item 1. Financial Statements.
FAQ
- What is MapLight Therapeutics, Inc.'s EPS (diluted)?
- MapLight Therapeutics, Inc. (MPLT) reported EPS (diluted) of -$1.34 in Q1 2026.
- How has MapLight Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- MapLight Therapeutics, Inc.'s EPS (diluted) increased by 95.4% year-over-year, from -$29.33 to -$1.34.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about MapLight Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude